We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Maximus Stock to Your Portfolio Now
Read MoreHide Full Article
Maximus, Inc. (MMS - Free Report) stands out as a strong investment opportunity, backed by solid fundamentals and a favorable Zacks rating. The company’s consistent financial performance, strategic acquisitions and strong government partnerships position it well for continued growth. With a history of stable dividend payments and a healthy liquidity position, Maximus demonstrates resilience and reliability in the market.
Let’s take a closer look at what makes MMS an attractive investment option.
MMS carries a Zacks Rank #2 (Buy). Our research shows that stocks with a Zacks Rank #1 (Strong Buy) or 2 offer attractive investment opportunities. Thus, the company appears to be a compelling investment proposition.
The Zacks Consensus Estimate for fiscal 2025 earnings is pegged at $6.08, representing a 1.3% increase over the past 60 days. One estimate for fiscal 2025 earnings has been revised upward, with no downward revisions in this time frame.
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise and its ability to deliver cost-effective, efficient and high-scale solutions position it as a lucrative partner to governments.
Maximus maintains solid relationships and a strong reputation with governments. Its long-term contracts provide the company with predictable recurring revenue streams. It continuously seeks long-term relationships with clients in not only those markets where they operate but also in adjacent ones.
Maximus has been active on the acquisition front,and this strategy has enabled itto expand its business processes, knowledge and client relationships, enhance technical capabilities and gain additional skill sets. Strategic acquisitions also complement the company’s long-term organic growth strategy. The 2022 acquisition of Stirling Institute of Australia, which provides vocational training to Australians seeking to improve their knowledge and qualifications, has strengthened its employment services. Another acquisition, BZ Bodies, has strengthened Maximus’ services within the U.K.
The company has a solid track record of dividend payments. During fiscal 2021, 2022, 2023 and 2024, Maximus paid cash dividends of $68.8 million, $68.7 million, $68 million and $72.9 million, respectively. These steady payouts indicate the company’s commitment to create value for shareholders and underline its confidence in its business.
Maximus' current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2025 was pegged at 1.72, higher than the industry’s 1.54. A current ratio of more than 1 indicates that the company should not have problems meeting its short-term obligations.
Image: Bigstock
Here's Why You Should Add Maximus Stock to Your Portfolio Now
Maximus, Inc. (MMS - Free Report) stands out as a strong investment opportunity, backed by solid fundamentals and a favorable Zacks rating. The company’s consistent financial performance, strategic acquisitions and strong government partnerships position it well for continued growth. With a history of stable dividend payments and a healthy liquidity position, Maximus demonstrates resilience and reliability in the market.
Let’s take a closer look at what makes MMS an attractive investment option.
MMS carries a Zacks Rank #2 (Buy). Our research shows that stocks with a Zacks Rank #1 (Strong Buy) or 2 offer attractive investment opportunities. Thus, the company appears to be a compelling investment proposition.
The Zacks Consensus Estimate for fiscal 2025 earnings is pegged at $6.08, representing a 1.3% increase over the past 60 days. One estimate for fiscal 2025 earnings has been revised upward, with no downward revisions in this time frame.
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise and its ability to deliver cost-effective, efficient and high-scale solutions position it as a lucrative partner to governments.
Maximus maintains solid relationships and a strong reputation with governments. Its long-term contracts provide the company with predictable recurring revenue streams. It continuously seeks long-term relationships with clients in not only those markets where they operate but also in adjacent ones.
Maximus has been active on the acquisition front,and this strategy has enabled itto expand its business processes, knowledge and client relationships, enhance technical capabilities and gain additional skill sets. Strategic acquisitions also complement the company’s long-term organic growth strategy. The 2022 acquisition of Stirling Institute of Australia, which provides vocational training to Australians seeking to improve their knowledge and qualifications, has strengthened its employment services. Another acquisition, BZ Bodies, has strengthened Maximus’ services within the U.K.
The company has a solid track record of dividend payments. During fiscal 2021, 2022, 2023 and 2024, Maximus paid cash dividends of $68.8 million, $68.7 million, $68 million and $72.9 million, respectively. These steady payouts indicate the company’s commitment to create value for shareholders and underline its confidence in its business.
Maximus, Inc. Dividend Yield (TTM)
Maximus, Inc. dividend-yield-ttm | Maximus, Inc. Quote
Maximus' current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2025 was pegged at 1.72, higher than the industry’s 1.54. A current ratio of more than 1 indicates that the company should not have problems meeting its short-term obligations.
Other Stocks to Consider
Some other top-ranked stocks are Affirm (AFRM - Free Report) and Baidu (BIDU - Free Report) .
Affirm sports a Zacks Rank of 1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AFRM has a long-term earnings growth expectation of 36.2%. It delivered a trailing four-quarter earnings surprise of 84.1% on average.
Baidu currently flaunts a Zacks Rank of 1.
BIDU has a long-term earnings growth expectation of 4.2%. It delivered a trailing four-quarter earnings surprise of 19.1% on average.